Key Highlights

  • Bloom Energy (NYSE:BE) rose about 9% on November 3, 2026, after Barclays reportedly upgraded it to Overweight while cutting its price target to USD 289.
  • Rivian (NASDAQ:RIVN) closed up 8.47% at USD 13.19 on November 2 after UBS upgraded it to Buy from Neutral, keeping a USD 17 price target, about 29% above the close on simple arithmetic.
  • CrowdStrike (NASDAQ:CRWD) fell about 3% on November 2 even after Deutsche Bank upgraded it to Buy from Hold and raised its target to USD 300 from USD 240.
  • Marvell Technology (NASDAQ:MRVL) fell 12.72% on November 2 and BofA cut it to Neutral from Buy, lowering its target to USD 225 from USD 400, citing roughly 50% share-count dilution.

Bloom Energy (NYSE:BE): An Upgrade With a Lower Target

Bloom Energy (NYSE:BE) shares rose about 9% on Tuesday, November 3, 2026, after published coverage reported that Barclays upgraded the stock to Overweight while cutting its price target to USD 289. Coverage cites the prior target as either USD 316 or USD 319, so the size of the cut is unclear, and the upgrade itself comes only from market recaps. The move followed an 11% drop on October 23 after third-quarter results and a rebound of about 7% on October 26, when shares were near USD 208. Third-quarter Revenue rose 138% to USD 1.24 billion and 2026 guidance was raised to USD 4.4 billion to USD 4.6 billion, but free Cash Flow was negative USD 180.6 million. Analysts have been split: some cut targets after the results, while Morgan Stanley raised its target to USD 335, according to published coverage. A rating change is an opinion on risk and reward, and a lower target with a higher rating shows the stock had fallen further than the analyst's value estimate. Fourth-quarter cash conversion is the test, and the CFO's comment that the cash use was not the beginning of a trend has to be borne out. Policy is a second risk, since a projected Democratic win in the Texas governor race raised fears of a Data Center moratorium, though none has taken effect.

Rivian (NASDAQ:RIVN): An Upgrade Against a Falling Tape

Rivian (NASDAQ:RIVN) reported third-quarter results on October 29, 2026, and the shares drifted lower until UBS analyst Joseph Spak raised the stock to Buy from Neutral on Monday, November 2, with an unchanged USD 17 target. Spak called the pullback a buying opportunity ahead of an expected inflection in R2 production and automotive gross margins. The stock gained 8.47% to USD 13.19 as the Nasdaq Composite fell 1.07%, so the move ran against the tape. UBS counted more than 103,000 R2 demonstration drives in the third quarter, nearly double the prior quarter, and expects Rivian to need no new Capital before 2029. That view depends on the R2 ramp lowering the cash burn, since free cash flow was negative USD 1.124 billion for the quarter and cash was USD 5.502 billion. A USD 1.000 billion Volkswagen Group term Loan arrived in October. The USD 17 target implies about 29% upside, simple arithmetic on two published numbers, and one analyst's view is not a consensus. The stock was still down roughly 36% for the year at one snapshot.

CrowdStrike (NASDAQ:CRWD): Good News in a Weak Group

CrowdStrike (NASDAQ:CRWD) shares fell about 3% on Monday, November 2, 2026, even though Deutsche Bank analyst Brad Zelnick upgraded the stock to Buy from Hold and raised the target to USD 300 from USD 240, about 24% above a close near USD 241.81, simple arithmetic. Zelnick cited a surge in cyber Demand as the AI frontier advances and said the company's own USD 565 billion estimate of its 2034 addressable market could prove conservative. CrowdStrike also expanded its Partnership with CoreWeave that day, though the original partnership dates from November 5, 2025, so only the expansion is new. Upgrades and partnerships often Fail to lift a stock when the whole group is being sold, and Cybersecurity peers weakened together by about 2% to 4% in early trading. The fundamentals were solid at the last report: ending annual Recurring Revenue of USD 5.84 billion, revenue of USD 1.47 billion and cash of about USD 5.01 billion. Valuation is the central risk, and GAAP Net Income was only USD 5.3 million in the quarter. Net new annual recurring revenue was USD 332.8 million, and any slowdown would draw attention quickly.

Marvell Technology (NASDAQ:MRVL): The Downgrade That Followed the Deal

Marvell Technology (NASDAQ:MRVL) agreed on November 2, 2026 to buy Lumentum in an all-stock deal at an implied Enterprise value of USD 115 billion, and the shares fell 12.72%. BofA cut Marvell to Neutral from Buy and its target to USD 225 from USD 400, citing roughly 50% share-count dilution, a long regulatory review and channel conflict. Several other analysts also downgraded, per published coverage. The deal pays 4.500 Marvell shares for each Lumentum share, and Marvell holders would own about 67% of the combined company. The company identified more than USD 1 billion of annual run-rate cost synergies and expects non-GAAP Earnings accretion in year one after closing, which is expected in the first half of 2028, and cites an expanded addressable market of USD 550 billion, a company estimate. The downgrades focus on dilution and timing, while the company focuses on synergies and the combined product set. A review that includes China and the integration of two large engineering organizations are the main risks, and a cut of about 44% in the target, simple arithmetic on USD 400 and USD 225, shows how strongly the analyst weighed them. Marvell also preliminarily reported fiscal third-quarter revenue and narrowed its guidance range to plus or minus 2%.

Where Things Stand

A single analyst call can move a stock, but only when it fits the existing mood. The Bloom and Rivian upgrades landed after falls, with Rivian rising against a down tape, while the CrowdStrike upgrade could not offset a group selloff and the Marvell downgrade followed a deal that investors disliked. The evidence is that calls amplify moves already underway rather than create them, and that a target is an opinion, not a forecast. Bloom Energy (NYSE:BE) and Rivian have the largest execution questions behind their upgrades. CrowdStrike (NASDAQ:CRWD) and Marvell face valuation and dilution questions. The next evidence is Bloom's cash conversion, Rivian's R2 ramp and Marvell's regulatory path.